Evaluation of Production Lots of a Rapid Point-of-Care Lateral Flow Serological Test Intended for Identification of IgM and IgG against the N-Terminal Part of the Spike Protein (S1) of SARS-CoV-2
- PMID: 34072890
- PMCID: PMC8230246
- DOI: 10.3390/v13061043
Evaluation of Production Lots of a Rapid Point-of-Care Lateral Flow Serological Test Intended for Identification of IgM and IgG against the N-Terminal Part of the Spike Protein (S1) of SARS-CoV-2
Abstract
The potential of rapid point-of-care (POC) tests has been subject of doubt due to an eventual risk of production errors. The aim was therefore to evaluate the two separate production lots of a commercial POC lateral flow test, intended for the detection of IgM and IgG against the SARS-CoV-2 spike protein (S1). Control samples consisted of serum from individuals with confirmed SARS-CoV-2 infection and pre-COVID-19 negative sera gathered from a biobank. The presence of anti-S1 IgM/IgG in the sera was verified by an in-house Luminex-based serological assay (COVID-19 SIA). One hundred samples were verified as positive for anti-S1 IgG and 74 for anti-S1 IgM. Two hundred samples were verified as negative for anti-S1 IgM/IgG. For the two lots of the POC-test, the sensitivities were 93.2% and 87.8% for IgM and 93.0% and 100% for IgG. The specificities were 100% for IgM and 99.5% for IgG. The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The negative predictive value was 97.6% and 95.7% for IgM, and 96.6% and 100% for IgG. The evaluated POC-test is suitable to assess anti-SARS-CoV-2 S1 IgM and IgG, as a measure of previous virus exposure on an individual level. The external validation of separate lots of rapid POC-tests is encouraged to ensure high sensitivity before market introduction.
Keywords: IgM/IgG; POC-test; S1; SARS-CoV-2; lateral flow; lot; specificity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021. PLoS One. 2021. PMID: 33661990 Free PMC article.
-
Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2.Viruses. 2021 May 26;13(6):993. doi: 10.3390/v13060993. Viruses. 2021. PMID: 34073484 Free PMC article.
-
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.J Med Virol. 2021 May;93(5):2857-2866. doi: 10.1002/jmv.26741. Epub 2021 Mar 1. J Med Virol. 2021. PMID: 33331654
-
Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review.Int J Infect Dis. 2021 Mar;104:415-422. doi: 10.1016/j.ijid.2021.01.016. Epub 2021 Jan 12. Int J Infect Dis. 2021. PMID: 33450372 Free PMC article.
-
Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies.Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10208-10218. doi: 10.26355/eurrev_202010_23243. Eur Rev Med Pharmacol Sci. 2020. PMID: 33090430 Review.
Cited by
-
Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study.Infect Dis Rep. 2022 Dec 11;14(6):1004-1016. doi: 10.3390/idr14060100. Infect Dis Rep. 2022. PMID: 36547246 Free PMC article.
-
Delayed Antibody Response in the Acute Phase of Infection Is Associated with a Lower Mental Component of Quality of Life in Survivors of Severe and Critical COVID-19.J Clin Med. 2024 Mar 27;13(7):1938. doi: 10.3390/jcm13071938. J Clin Med. 2024. PMID: 38610703 Free PMC article.
-
Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19.Front Bioeng Biotechnol. 2022 May 3;10:866368. doi: 10.3389/fbioe.2022.866368. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35592553 Free PMC article. Review.
References
-
- Worldometer COVID-19 Coronavirus Pandemic. [(accessed on 7 March 2021)]; Available online: https://www.worldometers.info/coronavirus/
-
- Pollan M., Perez-Gomez B., Pastor-Barriuso R., Oteo J., Hernan M.A., Perez-Olmeda M., Sanmartin J.L., Fernandez-Garcia A., Cruz I., Fernandez de Larrea N., et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–544. doi: 10.1016/S0140-6736(20)31483-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous